Guardant Health, Inc.
- GH
- NASDAQ
- Medical - Diagnostics & Research
- Liquid Biopsy/Oncology Diagnostics
- Blood-Based Cancer Testing
$157.83
Today −0.48%Quote Oct 19, 2026, 01:55 PM UTC
−13.38%over the last month
Max drawdown −15.3%From 1-month high −15.3%3 months +7.1%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$21.18B
Quote Oct 19
Next earnings
Nov 5
Expected, not confirmed
Analyst target
$202.40
+28.2% from here
Floor
$154.65
2.0% below price
Where the price sits
31 analysts
Analyst range, low to high
$180.00$225.00
- Price $157.83
- Resistance $161.19–$162.81
- Consensus $202.40
The price is right under resistance. Analysts' average target sits about 28% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about GHPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
Q2 2026 revenue $335.0M
- Oncology$219.1M65.4%
- Biopharma & Data$60.9M18.2%
- Screening$52.9M15.8%
- Licensing & Other$2.1M0.6%
Industry
Medical - Diagnostics & Research
Employees
2,498